×
About 1,554 results
2019 Supportive Care: Anxiety, Depression, and Low Social Support Are Significant Factors in Cancer Pain Intensity
https://ascopost.com/news/october-2019/anxiety-depression-and-low-social-support-are-significant-factors-in-cancer-pain-intensity/

Oct 21st, 2019 - Pain is one of the most common symptoms associated with cancer and its treatment, and feelings of anxiety and depression can intensify the level of pain patients experience, according to the results from a study by Galloway et al that will be presented at the 2019 Supportive Care in Oncology Symposium (Abstract 76). However, authors also reported that having greater social support can help miti...

Statement on the FDA’s benefit-risk framework for evaluating opioid analgesics
https://www.fda.gov/news-events/press-announcements/statement-fdas-benefit-risk-framework-evaluating-opioid-analgesics

Jun 19th, 2019 - Addressing the crisis of opioid addiction is an issue of great concern for our nation and remains a top public health priority for the FDA. The agency continues to take new steps to confront this crisis, while also paying careful attention to the needs of patients in accessing appropriate pain management. Opioids present unique challenges: they have benefits when used as prescribed yet have ver...

Pain Management Best Practices Interagency Task Force Report
https://www.hhs.gov/sites/default/files/pmtf-final-report-2019-05-23.pdf

May 7th, 2019 - Patients with acute and chronic pain in the United States face a crisis because of significant challenges in obtaining adequate care, resulting in profound physical, emotional, and societal costs. According to the Centers for Disease Control and Prevention, 50 million adults in the United States have chronic daily pain, with 19.6 million adults experiencing highimpact chronic pain that interf...

NCCN 2019 Annual Conference Includes Focus on Patient Experience with Innovative Therapies, Plus Updates on Biomarkers, Biosimilars, and the Latest Research on Cancer Care
https://www.nccn.org/about/news/newsinfo.aspx?NewsID=1437

Mar 3rd, 2019 - More than 1,500 cancer care professionals are meeting in Orlando, Florida, March 21-23, for the NCCN 2019 Annual Conference, presented by the National Comprehensive Cancer Network® (NCCN®)—an alliance of 28 leading cancer centers. The conference offers more than 25 sessions presenting the latest treatment recommendations for lung, breast, prostate, colon, and other cancers, including new and em...

Challenges with Implementing the Centers for Disease Control and Prevention Opioid Guideline: A Consensus Panel Report
https://academic.oup.com/painmedicine/advance-article-abstract/doi/10.1093/pm/pny307/5301726?redirectedFrom=fulltext
Kroenke, K. et. al.

Jan 24th, 2019 - A national crisis of opioid-related morbidity, mortality, and misuse has led to initiatives to address the appropriate role of opioids to treat pain. Deployment of a guideline from the Centers for Disease Control and Prevention to reduce the risks of opioid therapy has raised substantial clinical and public policy challenges. The agency anticipated implementation challenges and committed to ree...

Opioids in Nursing Homes
https://paltc.org/opioids%20in%20nursing%20homes

Dec 3rd, 2018 - AMDA – The Society for Post-Acute and Long-Term Care Medicine has two primary policies related to opioids in nursing homes: 1. Provide access to opioids when indicated to relieve suffering and to improve or maintain function, and 2. Promote opioid tapering, discontinuation and avoidance of opioids when the above goals are not achievable, to prevent adverse events, dependence and diversion.

MORPHABOND™ ER (morphine sulfate) Prescribing Information
https://dsi.com/prescribing-information-portlet/getPIContent?productName=Morphabond&inline=true

Nov 30th, 2018 - MORPHABOND ER is an opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

ROXYBOND (oxycodone hydrochloride) Prescribing Information
https://dsi.com/prescribing-information-portlet/getPIContent?productName=Roxybond&inline=true

Nov 30th, 2018 - ROXYBOND is an opioid agonist indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Persistent Postsurgical Pain: Pathophysiology and Preventative Pharmacologic Considerations
http://anesthesiology.pubs.asahq.org/article.aspx?articleid=2681077
Richebe, P. et. al.

Aug 31st, 2018 - The development of chronic pain is considered a major complication after surgery. Basic science research in animal models helps us understand the transition from acute to chronic pain by identifying the numerous molecular and cellular changes that occur in the peripheral and central nervous systems. It is now well recognized that inflammation and nerve injury lead to long-term synaptic plastici...

MORPHABOND ER Medication Guide
https://dsi.com/prescribing-information-portlet/getPIContent?productName=Morphabond%20Med&inline=true

May 31st, 2018 - MORPHABOND ER is: A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage pain severe enough to require daily around-the clock, long-term treatment with an opioid, when other pain treatments such as non-opioid pain medicines or immediate-release opioid medicines do not treat your pain well enough or you cannot tolerate them.

Risk Factors for Opioid Use Disorders in Adult Postsurgical Patients
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040780/
Burcher, K. et. al.

May 10th, 2018 - The use of opioids in the treatment of chronic pain is one of the most controversial topics in medicine today. Many studies have proposed that the postoperative period is a vulnerable time for patients at risk for developing an opioid use disorder. Many patients are prescribed opioids for management of their postsurgical pain and continue using them for prolonged amounts of time following their...

Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients
https://www.aacc.org/science-and-practice/practice-guidelines/using-clinical-laboratory-tests-to-monitor-drug-therapy-in-pain-management-patients

Oct 31st, 2017 - The American Association for Clinical Chemistry (AACC) Academy, formerly the National Academy of Clinical Biochemistry (NACB), has developed a laboratory medicine practice guidelines (LMPG) for using laboratory tests to monitor drug therapy in pain management patients. The scope and purpose of this guideline was to compile evidence-based recommendations for the use of laboratory and point-of-ca...

Daiichi Sankyo, Inc. and Inspirion Delivery Sciences LLC Announce Plans for Commercialization of RoxyBond™ (oxycodone hydrochloride) Tablets CII in the U.S.
https://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006638.html

May 30th, 2017 - Daiichi Sankyo, Inc. and Inspirion Delivery Sciences LLC (Inspirion) announced today that Daiichi Sankyo will lead the U.S. commercialization of FDA-approved RoxyBond™ (oxycodone hydrochloride) immediate-release tablets, for oral use, CII with Inspirion providing additional salesforce as part of Inspirion’s co-promotion rights under the License Agreement. RoxyBond is indicated for the managemen...

Behavioral Medicine: How to Incorporate Into Pain Management
https://www.practicalpainmanagement.com/treatments/psychological/cognitive-behavioral-therapy/behavioral-medicine-how-incorporate-pain

May 11th, 2017 - There is a great deal of evidence to support the effectiveness of various cognitive-behavioral interventions for reducing pain intensity and improving a patient’s coping skills. Behavioral medicine approaches aim to modify the overall pain experience, help restore functioning, and improve the quality of life of patients who suffer from chronic pain. The most common interventions include accepta...

ROXYBOND (oxycodone hydrochloride) Medication Guide
https://dsi.com/prescribing-information-portlet/getPIContent?productName=Roxybond_Med&inline=true

Mar 31st, 2017 - ROXYBOND is: A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage pain severe enough to require an opioid pain medicine, when other pain treatments such as nonopioid pain medicines do not treat your pain well enough or you cannot tolerate them.

Chronic postsurgical pain and persistent opioid use following surgery: the need for a transitional pain service
https://www.futuremedicine.com/doi/10.2217/pmt-2016-0004
Huang, A. et. al.

Jul 5th, 2016 - Aim: To identify the 3-month incidence of chronic postsurgical pain and long-term opioid use in patients at the Toronto General Hospital. Methods: 200 consecutive patients presenting for elective major surgery completed standardized questionnaires by telephone at 3 months after surgery. Results: 51 patients reported a preoperative chronic pain condition, with 12 taking opioids preoperatively. 3...

A practical guide to tapering opioids
https://mhc.cpnp.org/doi/full/10.9740/mhc.2015.05.102
Kral, L. et. al.

Apr 30th, 2015 - Tapering opioids is one of the most daunting dilemmas in clinical practice today. The decision to taper opioids is based on many factors, including a lack of efficacy, unacceptable risk, perioperative management, noncompliance, or patient preference. Tapering in the perioperative setting is quite common, though more complex in patients previously taking chronic opioid therapy. Outside of a medi...

Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain
https://www.nejm.org/doi/10.1056/NEJMoa1310246
Chey, W. et. al.

Jun 18th, 2014 - Opioid-induced constipation is common and debilitating. We investigated the efficacy and safety of naloxegol, an oral, peripherally acting, μ-opioid receptor antagonist, for the treatment of opioid-induced constipation. In two identical phase 3, double-blind studies (study 04, 652 participants; study 05, 700 participants), outpatients with noncancer pain and opioid-induced constipation were ran...

TARGINIQ ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets) Prescribing Information
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205777lbl.pdf

TARGINIQ ER is a combination product consisting of oxycodone, an opioid agonist, and naloxone, an opioid antagonist, indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

XARTEMIS XR (oxycodone hydrochloride and acetaminophen) Prescribing Information
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204031s000lbl.pdf

XARTEMIS XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets is a combination of oxycodone, an opioid agonist, and acetaminophen, and is indicated for the management of acute pain severe enough to require opioid treatment and for which alternative treatment options are inadequate.